Eyepoint Pharmaceuticals, Inc. (EYPT) — 10-Q Filings
All 10-Q filings from Eyepoint Pharmaceuticals, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
EyePoint's R&D Soars, Net Loss Widens Amid DURAVYU Trials
— Nov 6, 2025 Risk: high
EyePoint Pharmaceuticals, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $164.35 million, up from $89.4 -
EyePoint's Q2 Loss Widens on Soaring R&D for Key Drug
— Aug 7, 2025 Risk: high
EyePoint Pharmaceuticals reported a net loss of $29.9 million for the quarter ended June 30, 2025, compared to a net loss of $28.3 million for the same period i -
EyePoint Pharmaceuticals Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
EyePoint Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as pSivida Corp., is incorporated in Delaware an -
EyePoint Pharmaceuticals Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
EyePoint Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the -
EyePoint Pharmaceuticals Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
EyePoint Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as pSivida Corp., reported financial results and -
EyePoint Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: medium
EyePoint Pharmaceuticals, Inc. (EYPT) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. EyePoint Pharmaceuticals, Inc. filed a 10-Q report for the pe
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX